

References

- **Abdelwhab S, Elshinnawy S (2008):** Pulmonary Hypertension in Chronic Renal Failure Patients. *Am J Nephrol*; 28:990–997.
- **Adekunle L, Schmidt F, Quist J et al., (2006):** Pulmonary hypertension in patients with ESRD. *Chest Meet Abstr*; 130: 253S.
- **Amin M, Fawzy A, Hamid MA et al., (2003):** Pulmonary hypertension in patients with chronic renal failure; role of parathyroid hormone and pulmonary artery calcifications. *Chest*; 124: 2093–2097.
- **Andrew S, Josef C, Ethan B et al., (2003):** National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. *Ann Intern Med.*; 139:137-147.
- **Anna R, Brad C, Paul M et al., (2010):** Pulmonary hypertension is prevalent in catheter and arterio-venous access hemodialysis. *Nephrology Reviews*; 2:e3.
- **Asmi M H. (1995):** Evaluation of intracardiac pressures. In: *Asmi M H and Walsh M J (eds): A Practical Guide to Echocardiography 1st ed. Chapman&Hall*; 189.
- **Badesch OB, Abman SH, Ahearn GS et al., (2004):** Medical therapy for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. *Chest*; 126:365-428
- **Barak M, Katz Y. (2005):** Microbubbles: pathophysiology and clinical implications. *Chest*; 128(4):2918-32.
- **Barst RJ, Mc Cown M, Tort A et al., (2004):** Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardio*; 43 (Suppl S): 40S-47S.

- **Beigi AA, Sadeghi AM, Khosravi AR, et al., (2009):** Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. *J Vasc Access*.;10(3):160-6
- **Bento AC, De Moraes S. (1992):** Effects of estrogen pretreatment of the spare alpha 1-adrenoceptors and the slow and fast components of the contractile response of the isolated female rat aorta. *General pharmacology*; 23(3):565-70
- **Berger M, Haimowitz A, Van Tosh P et al., (1985):** Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. *J Am Coll Cardiol*; 6(2):359-65.
- **Besarab A , Ravi K, Parasurman et al., (1999):** Vascular Access for Hemodialysis. In: Hartmut H, Malluche (eds): *Clinical Nephrology, Dialysis and Transplantation*. Lexington, July.pp1
- **Besarab A, Zasuwa G, Frinak S et al., (1996) :** Survival of arteriovenous native fistulae (NF) exceeds that of prosthetic bridge grafts. *J Am Soc Nephrol*; 9: 1403.
- **Bevan RD. (1989):** Influence of adrenergic innervations on vascular growth and mature characteristics. *Am Rev Respir Dis*.; 140(5):1478-82.
- **Bossone E, Bodini BD, Mazza A, et al., (2005):** Pulmonary arterial hypertension: the key role of echocardiography. *Chest*; 127:1836–43.
- **Bossone E, Duong-Wagner TH, Paciocco G, et al., (1999):** Echocardiographic features of primary pulmonary hypertension. *J Am Soc Echocardiogr*.; 12:655–62.
- **Botney MD, Bahadori L, Gold LI. (1994):** Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. *Am J Pathol*; 144(2): 286–295.

- **Cacciapuoti F, D'Avino M, Lama D et al., (1993):** Hemodynamic changes in pulmonary circulation induced by effort in the elderly. *Am J Cardiol*; 71(16):1481-4.
- **Cacoub P, Dorent R, Nataf P et al., (1997):** Endothelin-1 in the lungs of patients with pulmonary hypertension. *Cardiovasc Res.*; 33(1):196-200.
- **Canan E, Hayriye S, Ekrem D et al., (2009):** Prevalence of and Factors Affecting Pulmonary Hypertension in Hemodialysis Patients. *Respiration*; 78:411-5.
- **Cargill R, Kiely D, Clark R et al., (1995):** Hypoxemia and release of endothelin-1. *Thorax*; 50:1308-1310.
- **Celermajer D.S., Marwick T. (2005):** Echocardiographic and right heart catheterization techniques in patients with pulmonary arterial hypertension. *International Journal of Cardiology*; 125: 294–303
- **Chazan JA, London MR, Pono L. (1990):** The impact of diagnosis-related groups on the cost of hospitalization for end-stage renal disease patients at Rhode Island Hospital from 1987-1990. *Am J Kid Dis*; 6: 523-525.
- **Chong C K, Muzoora M, Eckert G J et al., (2009):** Medication changes based on echocardiography in dialysis patients. *Hemodialysis International*; 13: 472–478.
- **Christou H, Magnani B, Morse DS et al., (1998):** Inhaled nitric oxide does not affect adenosine 5'-diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn. *Pediatrics*; 102(6):1390-3.

- **Clarkson MR, Giblin L, Brown A et al., (2002):** Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. *Am J Kidney Dis*; 40:E8.
- **Cooper CJ, Jevnikar FW, Walsh T et al., (1998):** The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. *Am J Cardiol*; 82(5):609-14.
- **Daniels LB, Krummen DE, Blanchard DG. (2004):** Echocardiography in pulmonary vascular disease. *Cardiol Clin*; 22:383–399.
- **Dawborn J.K. (1996):** Chronic Renal Failure. In: Whitworth A, Lawrence JR and Kincaid Smith P (eds): Text book of Renal Disease, 2nd ed, *Churchill Livingstone*, PP 343 – 362.
- **Deanfiek J, Thautow E, Wames C et al., (2003):** Management of grown up congenital heart disease. *Eur Heart J*; 24(11): 1035-84.
- **Deng Z, Morse JH, Slager SL et al., (2000):** Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor gene. *Am J Hum Genet*; 67(3):737-44.
- **Diller GP, Dbnopoulos K, Okonko et al.,(2005):** Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. *Circulation*; 112(6): 828-35.
- **Eddahibi S, Humbert M, Fadel E et al., (2002):** Hyperplasia of pulmonary artery smooth muscle cells is causally related to over expression of the serotonin transporter in primary pulmonary hypertension. *Chest*; 121(Suppl):97S-98S.

- **FaberaL, Heemannb A, Sürigb M et al., (1998):** Outflow Acceleration Assessed by Continuous-Wave Doppler Echocardiography in Left Ventricular Hypertrophy: An Analysis of 103 Consecutive Cases. *Cardiology*;90:220-226
- **Fanburg BL, Lee SL. (1997):** New role for an old molecule: Serotonin as mitogen. *Am J Physiol*; 272(5 Pt 1):L795-806.
- **Gaine SP, Rubin U. (1998):** Primary Pulmonary Hypertension. *Lancet*; 352: 719-25.
- **Gale N, Ghofrani HA, Torbicki A, et al. (2005):** Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*; 353:2148-57.
- **Galie N, Grigioni F. Bacchi R L et al., (1996):** Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. *Eur J Clin Invest.*; 26(suppl 1):A48.
- **Galie N, Torbicki A, Barst R et al. (2004):** Guidelines on diagnosis and .treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *Eur Heart J*; 25:2243-78.
- **Galte N, Manes A, Branzi A. (2003):** Emerging medical therapies for pulmonary arterial hypertension. *Prog. Cardiovasc Dis*;45:213-24
- **Geoffrey J B, (2008):** Associations Between Two Quantitative Variables: Regression and Correlation. In: *Lesile D, Geoffrey J B (eds); Interpretation and Uses of Medical Statistics 5th edition, oxford scientific publication; Wiley-Blackwell ; pp.315-338.*

- **Giaid A, Yanagisawa M, Langleben D et al., (1993):** Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med.*; 328(24):1732-9.
- **Gray MO, Long CS, Kalinyak JE et al., (1998):** Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. *Cardiovasc Res*; 40(2):352-63.
- **Hachulla E, Coghlan JG. (2004):** A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. *Arm Rheum Dis*; 63:1009-14.
- **Hakim RM, Lazarus JM. (1995):** Initiation of dialysis. *J Am Soc Nephrol*; 6: 1319-1328.
- **Haris M , Usman U, Sangwan S et al., (2006):** prevalence of pulmonary hypertension in patients with renal insufficiency and obesity. *Chest* ;130: 253S
- **Hatle L, Angelsen BA, Tromsdal A. (1981):**Non-invasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. *Br Heart J*; 45:157–65.
- **Havlucu Y, Kursat S, Ekmekci C et al., (2007):** Pulmonary hypertension in patients with chronic renal failure. *Respiration*; 74: 503–510.
- **Heidi M. Connolly Jae K. Oh. (2007):** Echocardiography. In: Peter L, Robert O, Douglas L and Douglas P ;(eds): *Braunwald's Heart disease. A textbook of cardiovascular medicine, 8th ed.* Philadelphia: WB Saunders; 656.
- **Held J, Port K, Wolfe A et al., (1996):** The dose of hemodialysis and patient mortality. *Kidney Int*; 50: 550-6

- **Hopkins WE, Ochoa LL, Richardson GW et al., (1996):** Comparison of the hemodynamic data and survival of adults with sever pulmonary hypertension Eisenmenger syndrome. *J Heart Lung transplant; 15(1 Pt 1):100-5.*
- **Horstman D, Frank D, Rich G. (1998):** prolonged inhaled NO attenuates hypoxic, but not monocrotalin-induced, pulmonary vascular remodeling in rats. *Aneth Analg ; 86:74-81.*
- **Hulsman AR, van den Anker JN. (1997):** Evolution and natural history of chronic lung disease of prematurity. *Monaldi Arch Chest; 52(3):272-7.*
- **Humbert M, Sitbon O. Chaouat A et al., (2006):** Pulmonary Arterial Hypertension in France: Results from a National Registry. *Am J Respir Crit Care Med; 173(9): 1023-30.*
- **Kanterman RY, Vesely TM, Pilgram TK et al., (1995):** Dialysis access grafts: Anatomic location of venous stenosis and results of angioplasty. *Radiology; 195: 135-9.*
- **Koh ET, Lee P, Gladman DO et al., (1996):** Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. *Br J Rheumatol; 35(10):989-93.*
- **Kolff WJ, Berk HTJ, Welle M et al., (1997):** The artificial kidney, a dialyzer with a great area. *J Am Soc Nephrol; 8(12):1959-65.*
- **Kovaliik EC, Schwab SJ. (1997):** Antibiotic prophylaxis for hemodialysis access placement. *Am J Kidney Dis; 30: 448.*
- **Kuo PC, Plotkin JS, Johnson LB et al., (1997):** Distinctive clinical feature of portopulmonary hypertension. *Chest; 112:980-6.*

- **Lesile D, (2008):** Associations Between Two Quantitative Variables: Regression and Correlation. *In: Lesile D, Geoffrey J B (eds); Interpretation and Uses of Medical Statistics 5th edition, oxford scientific publication; Wiley-Blackwell ; pp.315-338.*
- **Lesile D, (2008):** Hypothesis Testing: General Principles and One-Sample Tests for Means, Proportions, Counts and Rates. *In: Lesile D, Geoffrey J B (eds); Interpretation and Uses of Medical Statistics 5th edition, oxford scientific publication; Wiley-Blackwell ; pp.116-142.*
- **Levin A. (2003):** The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). *Nephrol Dial Transplant* 18: 1446- 1451.
- **Locatelli F, Marcelli D, Conte F et al., (2000):** Cardiovascular disease in chronic renal failure: the challenge continues. *Nephrol Dial Transplant*; 15: 69–80.
- **Locatelli F, Bommer J, London GM et al., (2001):** Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. *Nephrol Dial Transplant*;16:459-468.
- **Lowrie EG, Laird NM, Parker TF et al., (1981):** Effect of the hemodialysis prescription on patient morbidity: Report from the National Cooperative Dialysis Study. *N Engl J Med*; 305: 1176-81.
- **Mac Greggor AJ, Canavan R, Knight C et al., (2001):** Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. *Rheumatology (Oxford).* ; 40(4):453-98.
- **Mac Rae JM, Levin A, Belenkie I. (2006):** The cardiovascular effects of arteriovenous fistulas in chronic kidney disease: A cause for concern? *Semin Dial*; 19:349–352.

- **Marangoni S, Quadri A, Dotti A, et al. (1988):** Noninvasive Assessment of pulmonary hypertension: a Simultaneous echo-Doppler hemodynamic study. *Cardiology*; 75: 401-8.
- **Mazdeh M, Mousavi S, Yahyazadeh H et al., (2008):** Pulmonary Hypertension in Hemodialysis Patients. *Saudi J Kidney Dis Transpl*;19:189-93
- **Mayes M D, (2003):** Endothelin and endothelin receptor antagonists in systemic rheumatic disease. *Arthritis & Rheumatism*; 48:1190-9.
- **McGoon M, Guttermann D, Steen V et al. (2004):** Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest*; 126:14S-34S.
- **Murtha YM, Allen BM, Orr JM. (1999):** The role of protein C in thromboxane A₂-induced pulmonary artery vasoconstriction. *J Biomed*; 6(4):293-5.
- **Mutlak D, Aronson D, Lessick J et al.,(2009):** Functional Tricuspid Regurgitation in Patients With PulmonaryHypertension : Is Pulmonary Artery Pressure the Only Determinant ofRegurgitation Severity? *Chest* ;135; 115-121
- **Naeije R, Torbicki A. (1995):** More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. *Eur Respir J*; 8:1445–9.
- **Nakhoul1 F, Yigla M, Gilman R et al., (2005):** The pathogenesis of pulmonary hypertension in Hemodialysis patients via arterio-venous access. *Nephrol Dial Transplant*; 20: 1686–1692

- **Nasri H, Shirani S, Baradaran A. (2006):** Pulmonary artery pressure in maintenance hemodialysis patients. *Pakistan journal of biological sciences*; 9(1); 107-10.
- **Oh JK, Seward JB, Tajik AJ . (2006):** Doppler Echocardiography and Color Flow Imaging: Comprehensive Noninvasive Hemodynamic Assessment. In: *Oh JK, Seward JB, Tajik AJ (eds): The Echo Manual. 3rd ed. Philadelphia, Lippincott Williams & Wilkins; 73.*
- **Okura H, Takatsu Y. (1994):** high output failure as cause of pulmonary hypertension. *Intern Med*; 33(6):363-5.
- **Ono F, Nagaya N, Okamura H et al. (2003):** Effect of orally active prostacyclin analogue on survival in patients with chronic thrombo embolic pulmonary hypertension without major vessel obstruction. *Chest*; 123:1583-8.
- **Peacock AJ. (2003):** Treatment of pulmonary hypertension. *BMJ*; 326:835-6.
- **Pietra G. (1997):** The pathology of primary pulmonary hypertension. In: *Rubin LJ, Rich S (eds): primary pulmonary hypertension. New York, Marcel Dekker; pp 19-61.*
- **Polashegg HD. (1995):** The extracorporeal circuit. *Seminars Dial* 8: 299-304.
- **Perazella M, Reilly R (2003):** Chronic kidney disease: A new classification and staging system. *Hospital physician*; 45:18-22.
- **Raffy O, Azarian R, Brenot F et al., (1996):** Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. *Circulation*; 93(3):484-8.

- **Rich S. (1988):** Primary pulmonary hypertension. *Prog Cardiovasc Dis*; 31(3):205-38.
- **Rubin LJ. (1995):** Pathology and pathophysiology of primary pulmonary hypertension. *Am J Cardiol*; 75: 51A–54A
- **Rubin LJ. (2002):** Therapy of pulmonary hypertension: the evolution from vasodilators to anti proliferative agents. *Am J Respir Crit Care Med*; 166:1308-9.
- **Rubin LJ, Badesch DB. (2005):** Evaluation and management of the patient with pulmonary arterial hypertension. *Ann Intern Med*; 143:282–92.
- **Rubin U. (2002):** pulmonary arterial hypertension. *N Engl J Med*; 34e:896-903.
- **Salvi SS. (1999):** Alpha1- adrenergic hypothesis for pulmonary hypertension. *Chest*; 115-1708.
- **Schuster DP, Crouch EC, Parks WC et al., (1996):** Angiotensin converting enzyme expression in primary pulmonary hypertension. *Am J Respir Crit Care Med*; 154(4 Pt 1):1087-91.
- **Sciomer S, Badagliacca R, Fedele F. (2005):** Pulmonary hypertension: echocardiographic assessment. *Ital Heart J*; 6:840–5.
- **Semenza GL, Agani F, Iyer N et al., (1998):** Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. *Chest*; 114:40S-45S.
- **Shammas R L , Khan N A,Nekkanti R et al.,(2007):** Diastolic heart failure and left ventricular diastolic dysfunction: What we know, and what we don't know!.*Int J Cardiol.*;115,3:284-292.

- **Simonneau G, Ivan M. Robbins et al., (2009):** Updated Clinical Classification of Pulmonary Hypertension. *J Am Coll Cardiol*; 54:S43–54).
- **Sitbon O, Gressin V, Speich R et al., (2004):** Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med*; 170(11): 1212-7.
- **Sitbon O, Humbert M, Jatt X et al., (2005):** Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation* ; 111: 3105-11
- **Speich R, Jenni R, Opravil M et al., (1991):** Primary pulmonary hypertension in HIV infection. *Chest*; 100:1268-71.
- **Stewart DJ, Levy RD, Commack P et al., (1991):** Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? *Ann Inter Med*; 114:464-9.
- **Tarrass F, Benjelloun M, Hachim K et al., (2005):** Pulmonary hypertension in patients with end-stage renal disease. *Indian J Nephrol*;15: 223-226.
- **.Tiwari SC, Bhowmik DM. (2008):** Staging of CKD: is a new stage needed? *Am J Kidney Dis.*;51(2):346.
- **Tramarin R, Torbicki A, Marchandise B et al., (1991):** Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. *Eur Heart J*; 12:103–11.

- **Un EE, Rodgers GP, Gladwin MT. (2005):** Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. *Curr Hematol Rep* ;4(2):117-25.
- **Vorwerk D, Schümann K, Müller-Leisse C et al., (1996):** Hydrodynamic thrombectomy of hemodialysis grafts and fistulae: results of 51 procedures. *Nephrol Dial Transplant*; 11: 1058-64.
- **Weir EK, Reeve HL, Huang JMC et al., (1996):** Anorexic agents: aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. *Circulation*; 94:2216–20.
- **Yigla M, Abassi Z, Shimon A et al., (2006):** Pulmonary hypertension in hemodialysis patients: an unrecognized threat. *Seminars In Dialysis* ; 19(5):353-7
- **Yigla M, Nakhoul F, Sabage A, et al. (2003):** pulmonary hypertension in patients with ESRD. *Chest*; 123:1577-82.
- **Yock PG, Popp RL. (1984):** Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. *Circulation*; 70:657–62.
- **Yoshiyoshi M, Nishitaka K, Nakao K et al., (1991):** Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. *Circulation*; 84: 2280-5